Ionis Pharmaceuticals Company Profile (NASDAQ:IONS)

About Ionis Pharmaceuticals

Ionis Pharmaceuticals logoIonis Pharmaceuticals, Inc., formerly Isis Pharmaceuticals, Inc., is engaged in discovering and developing ribonucleic acid-targeted (RNA-targeted) therapeutics. The Company operates through two segments: Ionis Core and Akcea Therapeutics. The Company's Ionis Core segment is developing a drug discovery platform. The Company's Akcea Therapeutics segment consists of the operations of its subsidiary, Akcea Therapeutics, Inc., which develops and commercializes drugs for cardiometabolic disorders. The Company is developing transformational drugs, which include nusinersen, IONIS-TTR and volanesorsen that are designed to treat patients with orphan diseases. In addition to its Phase III programs, the Company has a pipeline of drugs in Phase II development, which includes IONIS-FXI and IONIS-APO(a)-L. Its Phase II pipeline includes drugs to treat patients with severe and rare diseases, viral infections, ocular diseases, metabolic disorders and cardiovascular diseases.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: IONS
  • CUSIP: 46433010
Key Metrics:
  • Previous Close: $33.71
  • 50 Day Moving Average: $30.83
  • 200 Day Moving Average: $33.23
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -33.38
  • P/E Growth: -0.80
  • Market Cap: $4.08B
  • Outstanding Shares: 120,919,000
  • Beta: 2.13
Additional Links:
Companies Related to Ionis Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Ionis Pharmaceuticals (NASDAQ:IONS) (?)
Ratings Breakdown: 1 Sell Rating, 7 Hold Ratings, 3 Buy Ratings
Consensus Rating:Hold (Score: 2.18)
Consensus Price Target: $38.78 (15.03% upside)

Analysts' Ratings History for Ionis Pharmaceuticals (NASDAQ:IONS)
Show:
DateFirmActionRatingPrice TargetDetails
8/19/2016Wells Fargo & Co.Reiterated RatingOutperformView Rating Details
8/18/2016Piper Jaffray Cos.Reiterated RatingOverweight$46.00View Rating Details
8/13/2016Cowen and CompanyReiterated RatingMarket PerformView Rating Details
8/11/2016Leerink SwannReiterated RatingHold$36.00View Rating Details
8/2/2016Barclays PLCBoost Price TargetEqual Weight$26.00 -> $41.00View Rating Details
8/2/2016Morgan StanleyInitiated CoverageEqual -> Equal Weight$37.00 -> $37.00View Rating Details
8/1/2016BMO Capital MarketsBoost Price TargetMarket Perform$25.00 -> $40.00View Rating Details
8/1/2016Needham & Company LLCBoost Price TargetBuy$55.00 -> $64.00View Rating Details
7/15/2016Jefferies GroupReiterated RatingUnderperform$12.00View Rating Details
5/29/2016JPMorgan Chase & Co.Reiterated RatingHoldView Rating Details
2/22/2016Goldman Sachs Group Inc.Lower Price Target$65.00 -> $48.00View Rating Details
6/22/2015Deutsche Bank AGSet Price TargetBuy$78.00View Rating Details
3/17/2015Janney Montgomery ScottInitiated CoverageNeutral -> NeutralView Rating Details
3/2/2015Stifel NicolausDowngradeBuy -> Hold$66.00View Rating Details
3/2/2015Brean CapitalDowngradeBuy -> HoldView Rating Details
12/9/2014LaidlawBoost Price Target$65.00View Rating Details
(Data available from 8/24/2014 forward)

Earnings

Earnings History for Ionis Pharmaceuticals (NASDAQ:IONS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2016        
8/9/2016Q216($0.52)($0.47)$38.52 million$38.50 millionViewN/AView Earnings Details
5/4/2016Q116($0.50)($0.52)$36.21 million$36.90 millionViewN/AView Earnings Details
2/25/2016Q415($0.47)($0.59)$49.32 million$51.60 millionViewListenView Earnings Details
11/9/2015Q315($0.31)($0.30)$52.93 million$49.10 millionViewN/AView Earnings Details
8/4/2015Q215$0.29$0.29$114.93 million$120.40 millionViewN/AView Earnings Details
5/5/2015Q115($0.19)($0.14)$52.74 million$62.60 millionViewN/AView Earnings Details
2/27/2015Q414$0.12$0.25$74.58 million$84.90 millionViewN/AView Earnings Details
11/7/2014Q314($0.20)($0.23)$45.79 million$44.10 millionViewN/AView Earnings Details
8/4/2014Q214($0.12)($0.10)$45.60 million$57.08 millionViewN/AView Earnings Details
5/6/2014Q114($0.23)($0.27)$35.12 million$28.20 millionViewN/AView Earnings Details
2/28/2014Q413($0.17)($0.21)$34.20 million$42.25 millionViewN/AView Earnings Details
11/5/2013Q313($0.27)($0.21)$19.82 million$23.60 millionViewN/AView Earnings Details
8/6/2013Q2 2013($0.21)($0.09)$26.76 million$38.10 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.02)($0.02)$45.24 million$43.36 millionViewListenView Earnings Details
2/28/2013Q4 2012($0.23)($0.03)$15.78 million$19.90 millionViewListenView Earnings Details
11/6/2012Q312($0.26)($0.37)$23.11 million$11.60 millionViewN/AView Earnings Details
8/6/2012($0.08)($0.01)ViewN/AView Earnings Details
5/8/2012($0.28)($0.24)ViewN/AView Earnings Details
2/29/2012($0.13)($0.20)ViewN/AView Earnings Details
11/7/2011($0.20)($0.27)ViewN/AView Earnings Details
8/4/2011($0.22)($0.18)ViewN/AView Earnings Details
5/5/2011($0.19)($0.20)ViewN/AView Earnings Details
2/28/2011($0.22)($0.14)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ionis Pharmaceuticals (NASDAQ:IONS)
Current Year EPS Consensus Estimate: $-1.12 EPS
Next Year EPS Consensus Estimate: $-1.01 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20162($0.50)($0.45)($0.48)
Q3 20162($0.02)$0.18$0.08
Q4 20162($0.29)($0.08)($0.19)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Ionis Pharmaceuticals (NASDAQ:IONS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Ionis Pharmaceuticals (NASDAQ:IONS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/31/2016Frederick T MutoDirectorSell12,500$22.31$278,875.00View SEC Filing  
4/6/2016Patrick R O'neilSVPSell1,000$45.00$45,000.00View SEC Filing  
4/6/2016Stanley T CrookeCEOSell11,000$46.13$507,430.00View SEC Filing  
3/31/2016Stanley T CrookeCEOSell11,000$40.74$448,140.00View SEC Filing  
3/23/2016Patrick R O'neilSVPSell1,000$45.40$45,400.00View SEC Filing  
1/19/2016B Lynne ParshallCOOSell5,192$41.46$215,260.32View SEC Filing  
1/19/2016C Frank BennettSVPSell2,110$41.46$87,480.60View SEC Filing  
1/19/2016Elizabeth L. HougenCFOSell1,899$41.46$78,732.54View SEC Filing  
1/19/2016Sarah BoyceinsiderSell872$41.46$36,153.12View SEC Filing  
1/19/2016Stanley T. CrookeCEOSell13,401$41.46$555,605.46View SEC Filing  
1/5/2016Stanley T. CrookeCEOSell5,500$62.10$341,550.00View SEC Filing  
1/4/2016B Lynne ParshallCOOSell809$61.05$49,389.45View SEC Filing  
1/4/2016Brett P. MoniaSVPSell127$61.00$7,747.00View SEC Filing  
1/4/2016Stanley T. CrookeCEOSell11,000$61.05$671,550.00View SEC Filing  
12/16/2015C Frank BennettSVPSell7,909$57.41$454,055.69View SEC Filing  
12/1/2015Patrick R. O'neilSVPSell1,000$61.50$61,500.00View SEC Filing  
11/11/2015Joseph Klein IIIDirectorSell6,875$64.18$441,237.50View SEC Filing  
11/10/2015C Frank BennettSVPSell5,000$64.00$320,000.00View SEC Filing  
11/6/2015C Frank BennettSVPSell5,000$56.00$280,000.00View SEC Filing  
11/3/2015Patrick R. O'neilSVPSell1,000$51.95$51,950.00View SEC Filing  
10/23/2015Stanley T. CrookeCEOSell44,000$43.85$1,929,400.00View SEC Filing  
10/2/2015B Lynne ParshallCOOSell12,436$40.75$506,767.00View SEC Filing  
7/6/2015B Lynne ParshallCOOSell6,218$57.01$354,488.18View SEC Filing  
7/6/2015Stanley T CrookeCEOSell5,000$57.01$285,050.00View SEC Filing  
7/1/2015B Lynne ParshallCOOSell6,218$57.56$357,908.08View SEC Filing  
7/1/2015Stanley T CrookeCEOSell6,175$57.56$355,433.00View SEC Filing  
6/8/2015Brett P MoniaSVPSell7,600$66.22$503,272.00View SEC Filing  
4/7/2015B Lynne ParshallCOOSell5,565$63.07$350,984.55View SEC Filing  
4/7/2015Stanley T CrookeCEOSell22,377$63.07$1,411,317.39View SEC Filing  
3/24/2015C Frank BennettSVPSell15,000$70.61$1,059,150.00View SEC Filing  
3/19/2015Elizabeth L HougenCFOSell10,000$73.33$733,300.00View SEC Filing  
3/19/2015Patrick R O'neilSVPSell30,525$74.85$2,284,796.25View SEC Filing  
3/2/2015Joseph H WenderDirectorSell7,000$65.97$461,790.00View SEC Filing  
1/27/2015Stanley T CrookeCEOSell11,000$72.93$802,230.00View SEC Filing  
1/16/2015B Lynne ParshallCOOSell4,093$67.96$278,160.28View SEC Filing  
1/16/2015Elizabeth L HougenCFOSell1,291$67.96$87,736.36View SEC Filing  
1/16/2015Richard S GearySVPSell1,543$67.96$104,862.28View SEC Filing  
1/16/2015Stanley T CrookeCEOSell9,054$67.96$615,309.84View SEC Filing  
1/9/2015Stanley T CrookeCEOSell11,000$73.57$809,270.00View SEC Filing  
1/7/2015Stanley T CrookeCEOSell22,000$67.04$1,474,880.00View SEC Filing  
1/2/2015B Lynne ParshallCOOSell11,200$62.12$695,744.00View SEC Filing  
1/2/2015Patrick R O'neilSVPSell1,500$62.12$93,180.00View SEC Filing  
12/1/2014Patrick R O'neilSVPSell1,500$51.21$76,815.00View SEC Filing  
11/3/2014Patrick R O'neilSVPSell1,500$46.17$69,255.00View SEC Filing  
10/30/2014B Lynne ParshallCOOSell11,071$45.12$499,523.52View SEC Filing  
10/23/2014Stanley T CrookeCEOSell14,600$42.22$616,412.00View SEC Filing  
10/3/2014Stanley T CrookeCEOSell36,000$38.52$1,386,720.00View SEC Filing  
10/1/2014Patrick R O'neilSVPSell1,500$38.04$57,060.00View SEC Filing  
10/1/2014Stanley T CrookeCEOSell20,000$37.91$758,200.00View SEC Filing  
8/27/2014C Frank BennettSVPSell5,000$40.53$202,650.00View SEC Filing  
8/13/2014Stanley T CrookeCEOSell15,500$35.45$549,475.00View SEC Filing  
8/12/2014Patrick R O'neilSVPSell1,500$35.00$52,500.00View SEC Filing  
8/1/2014Stanley T CrookeCEOSell16,000$30.53$488,480.00View SEC Filing  
7/31/2014Brett P MoniaSVPSell79$31.50$2,488.50View SEC Filing  
7/1/2014Patrick R O'neilSVPSell1,500$35.33$52,995.00View SEC Filing  
7/1/2014Stanley T CrookeCEOSell17,500$35.57$622,475.00View SEC Filing  
6/23/2014C Frank BennettSVPSell11,200$36.78$411,936.00View SEC Filing  
6/19/2014Stanley T CrookeCEOSell11,000$35.10$386,100.00View SEC Filing  
6/10/2014Stanley T CrookeCEOSell11,000$33.46$368,060.00View SEC Filing  
6/2/2014Frederick T MutoDirectorSell10,000$28.59$285,900.00View SEC Filing  
4/2/2014Stanley CrookeCEOSell8,800$43.65$384,120.00View SEC Filing  
1/30/2014B Lynne ParshallCOOSell89,510$49.49$4,429,849.90View SEC Filing  
1/24/2014Joseph Klein IIIDirectorSell10,313$48.66$501,830.58View SEC Filing  
1/22/2014Joseph WenderDirectorSell10,000$50.98$509,800.00View SEC Filing  
1/22/2014Richard GearySVPSell22,200$50.05$1,111,110.00View SEC Filing  
1/16/2014B Lynne ParshallCOOSell1,641$47.08$77,258.28View SEC Filing  
1/16/2014Stanley CrookeCEOSell3,527$47.08$166,051.16View SEC Filing  
1/8/2014Richard GearySVPSell15,000$40.45$606,750.00View SEC Filing  
1/8/2014Stanley CrookeCEOSell12,500$40.05$500,625.00View SEC Filing  
1/2/2014Stanley CrookeCEOSell31,500$39.35$1,239,525.00View SEC Filing  
12/26/2013B Lynne ParshallCOOSell37,811$40.91$1,546,848.01View SEC Filing  
12/24/2013B Lynne ParshallCOOSell70,000$41.49$2,904,300.00View SEC Filing  
12/20/2013Joseph WenderDirectorSell19,731$39.58$780,952.98View SEC Filing  
12/5/2013C Frank BennettSVPSell10,000$39.92$399,200.00View SEC Filing  
11/26/2013Joseph WenderDirectorSell10,000$36.63$366,300.00View SEC Filing  
9/20/2013B Lynne ParshallCOOSell90,000$35.43$3,188,700.00View SEC Filing  
9/20/2013Brett MoniaSVPSell68,281$34.21$2,335,893.01View SEC Filing  
9/20/2013Stanley CrookeCEOSell58,740$35.19$2,067,060.60View SEC Filing  
9/19/2013C Frank BennettSVPSell10,000$35.02$350,200.00View SEC Filing  
9/11/2013B Lynne ParshallCOOSell63,505$31.04$1,971,195.20View SEC Filing  
9/9/2013C Frank BennettSVPSell10,000$30.23$302,300.00View SEC Filing  
9/4/2013Patrick R O'neilSVPSell2,500$27.09$67,725.00View SEC Filing  
8/26/2013Brett MoniaSVPSell2,909$25.58$74,412.22View SEC Filing  
8/9/2013Joseph Klein IIIDirectorSell18,750$28.22$529,125.00View SEC Filing  
7/23/2013Stanley T CrookeCOOSell11,500$30.00$345,000.00View SEC Filing  
7/22/2013Stanley T CrookeCEOSell62,200$30.50$1,897,100.00View SEC Filing  
7/17/2013Stanley T CrookeCEOSell49,300$33.12$1,632,816.00View SEC Filing  
7/12/2013Stanley T CrookeCEOSell90,000$31.75$2,857,500.00View SEC Filing  
7/11/2013Richard S GearySVPSell9,000$31.90$287,100.00View SEC Filing  
7/9/2013Richard S GearySVPSell66,163$30.03$1,986,874.89View SEC Filing  
7/9/2013Stanley T CrookeCEOSell109,172$26.69$2,913,800.68View SEC Filing  
7/3/2013Richard S GearySVPSell5,000$29.02$145,100.00View SEC Filing  
7/1/2013Stanley T CrookeCEOSell50,683$27.65$1,401,384.95View SEC Filing  
6/26/2013Stanley T CrookeCEOSell90,000$26.73$2,405,700.00View SEC Filing  
6/25/2013Richard S GearySVPSell47,049$26.20$1,232,683.80View SEC Filing  
6/20/2013Joseph H WenderDirectorSell5,447$20.93$114,005.71View SEC Filing  
6/11/2013Brett P MoniaSVPSell9,375$23.76$222,750.00View SEC Filing  
5/30/2013Frederick T MutoDirectorSell10,000$21.96$219,600.00View SEC Filing  
1/16/2013Stanley T CrookeCEOSell1,460$14.00$20,440.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Ionis Pharmaceuticals (NASDAQ:IONS)
DateHeadline
istreetwire.com logoStocks Highlights: Danaher (DHR), Ionis Pharmaceuticals (IONS), Capital One Financial (COF) - iStreetWire (NASDAQ:IONS)
istreetwire.com - August 23 at 10:02 AM
News IconIonis Pharmaceuticals Inc. (NASDAQ: IONS) Outperform Rating Reiterated at Wells Fargo & Co. - BNB Daily (blog) (NASDAQ:IONS)
www.baseball-news-blog.com - August 23 at 10:02 AM
4-traders.com logoISIS Pharmaceuticals : Ionis Pharmaceuticals' CEO, Dr. Stanley Crooke, Receives E. B. Hershberg Award from the American Chemical Society (NASDAQ:IONS)
www.4-traders.com - August 22 at 10:16 AM
publicnow.com logoIonis Pharmaceuticals' CEO, Dr. Stanley Crooke, Receives E. B. Hershberg Award from the American Chemical Society (NASDAQ:IONS)
www.publicnow.com - August 22 at 10:16 AM
News IconThe Key Numbers To Watch From Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)'s Earnings - The Voice Registrar (NASDAQ:IONS)
voiceregistrar.com - August 19 at 8:38 AM
News IconIonis Pharmaceuticals Inc. (NASDAQ: IONS) Overweight Rating Reiterated at Piper Jaffray Cos. - BNB Daily (blog) (NASDAQ:IONS)
www.baseball-news-blog.com - August 19 at 8:38 AM
smarteranalyst.com logoWells Fargo Boosts Valuation Range on Ionis Pharmaceuticals Inc (IONS); Here's Why - Smarter Analyst (NASDAQ:IONS)
www.smarteranalyst.com - August 19 at 8:38 AM
smarteranalyst.com logoWells Fargo Boosts Valuation Range on Ionis Pharmaceuticals Inc (IONS); Here’s Why (NASDAQ:IONS)
www.smarteranalyst.com - August 18 at 5:41 PM
finance.yahoo.com logoIONIS PHARMACEUTICALS INC Financials (NASDAQ:IONS)
finance.yahoo.com - August 18 at 5:41 PM
fool.com logoIonis Pharmaceuticals Inc Begins to Shift Focus (NASDAQ:IONS)
www.fool.com - August 16 at 5:50 PM
smarteranalyst.com logoPiper Jaffray Positive on Ionis Pharmaceuticals Inc (IONS); Sees Bright Future Ahead - Smarter Analyst (NASDAQ:IONS)
www.smarteranalyst.com - August 16 at 12:19 PM
smarteranalyst.com logoPiper Jaffray Positive on Ionis Pharmaceuticals Inc (IONS); Sees Bright Future Ahead (NASDAQ:IONS)
www.smarteranalyst.com - August 15 at 9:13 PM
smarteranalyst.com logoCowen Top Analyst Cautious on Ionis Pharmaceuticals Inc (IONS); Here's Why - Smarter Analyst (NASDAQ:IONS)
www.smarteranalyst.com - August 12 at 8:52 AM
capitalcube.com logoETF’s with exposure to Ionis Pharmaceuticals, Inc. : August 11, 2016 (NASDAQ:IONS)
www.capitalcube.com - August 11 at 5:56 PM
smarteranalyst.com logoCowen Top Analyst Cautious on Ionis Pharmaceuticals Inc (IONS); Here’s Why (NASDAQ:IONS)
www.smarteranalyst.com - August 10 at 5:57 PM
fidaily.com logoBaillie Gifford & Co Adjusts Its Position in Ionis Pharmaceuticals, Inc ... - Finance Daily (NASDAQ:IONS)
www.fidaily.com - August 10 at 8:36 AM
finance.yahoo.com logoEdited Transcript of IONS earnings conference call or presentation 9-Aug-16 3:30pm GMT (NASDAQ:IONS)
finance.yahoo.com - August 10 at 8:36 AM
smarteranalyst.com logoCompany Update (NASDAQ:IONS): Ionis Pharmaceuticals Inc Reports Financial Results and Highlights for Second Quarter 2016 (NASDAQ:IONS)
www.smarteranalyst.com - August 9 at 5:52 PM
finance.yahoo.com logoIonis Pharmaceuticals' (IONS) Q2 Loss Lower than Expected (NASDAQ:IONS)
finance.yahoo.com - August 9 at 5:52 PM
thestreet.com logoWill Ionis Pharmaceuticals (IONS) Stock Be Helped By Q2 Revenue Beat, Guidance? (NASDAQ:IONS)
www.thestreet.com - August 9 at 5:52 PM
News IconStock's Earnings Analysis: Ionis Pharmaceuticals Inc (NASDAQ:IONS) - Post Registrar (NASDAQ:IONS)
postregistrar.com - August 9 at 8:42 AM
sg.finance.yahoo.com logoIonis Pharmaceuticals reports 2Q loss (NASDAQ:IONS)
sg.finance.yahoo.com - August 9 at 8:42 AM
streetupdates.com logoNotable Analyst's Ranking Preview: Ocular Therapeutix, Inc ... - Street Updates (NASDAQ:IONS)
www.streetupdates.com - August 8 at 10:22 AM
News IconInfluential Analyst Rating Changes: Ionis Pharmaceuticals, Inc ... - TWN (NASDAQ:IONS)
thewellesleysnews.com - August 8 at 10:22 AM
finance.yahoo.com logoWhy Earnings Season Could Be Great for Ionis Pharmaceuticals (IONS) (NASDAQ:IONS)
finance.yahoo.com - August 8 at 10:22 AM
News IconThe Statistics Don't Lie: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ... - The Voice Registrar (NASDAQ:IONS)
voiceregistrar.com - August 6 at 8:33 AM
thestreet.com logoBiotech Stock Mailbag: Ionis, Trust Issues and 'Oops! Don't Look at That Slide Deck' (NASDAQ:IONS)
www.thestreet.com - August 5 at 8:40 AM
finance.yahoo.com logoIonis Pharmaceuticals (IONS) Q2 Earnings: Stock to Beat? (NASDAQ:IONS)
finance.yahoo.com - August 4 at 5:57 PM
streetupdates.com logoNotable Analysts Recommendation to Monitor: Ionis ... - Street Updates (NASDAQ:IONS)
www.streetupdates.com - August 4 at 8:42 AM
smarteranalyst.com logoBarclays Boosts Price Target on Ionis Pharmaceuticals Inc (IONS) Following Positive Nusinersen Phase 3 Results - Smarter Analyst (NASDAQ:IONS)
www.smarteranalyst.com - August 4 at 8:42 AM
News IconIonis Pharmaceuticals Receives $75 Million From Biogen (NASDAQ:IONS)
sdbj.com - August 3 at 5:59 PM
breakingfinancenews.com logoBarclays Capital disclosed (NASDAQ:IONS) Ionis Pharmaceuticals Inc, upping its stock price target to $41 today (NASDAQ:IONS)
breakingfinancenews.com - August 3 at 5:59 PM
finance.yahoo.com logoCoverage initiated on Ionis Pharma by Morgan Stanley (NASDAQ:IONS)
finance.yahoo.com - August 3 at 5:59 PM
News IconHC Stocks Judgment: Ionis Pharmaceuticals Inc (NASDAQ:IONS), IDEXX Laboratories, Inc. (NASDAQ:IDXX) - share market updates (press release) (NASDAQ:IONS)
sharemarketupdates.com - August 3 at 8:53 AM
smarteranalyst.com logoCowen Top Analyst Bullish on Ionis Pharmaceuticals Inc (IONS) After Infant Muscle Disorder Drug Nusinersen Shines - Smarter Analyst (NASDAQ:IONS)
www.smarteranalyst.com - August 3 at 8:53 AM
biz.yahoo.com logoIONIS PHARMACEUTICALS INC Files SEC form 8-K, Other Events (NASDAQ:IONS)
biz.yahoo.com - August 3 at 8:53 AM
kcregister.com logoEarly Session Gainers: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), Central European Media Enterprises Ltd ... - KC Register (NASDAQ:IONS)
www.kcregister.com - August 2 at 5:54 PM
finance.yahoo.com logoBiogen (BIIB) Stock Surges 8% on Takeover Rumors (NASDAQ:IONS)
finance.yahoo.com - August 2 at 5:54 PM
schaeffersresearch.com logoIonis Pharmaceuticals Inc (IONS) Drug Data Puts Short Sellers on Notice (NASDAQ:IONS)
www.schaeffersresearch.com - August 2 at 10:29 AM
fool.com logoWhy Ionis Pharmaceuticals Inc Skyrocked Higher Today (NASDAQ:IONS)
www.fool.com - August 2 at 10:29 AM
News IconIonis shares leap 30% after a drug trial goes so well, it ends early (NASDAQ:IONS)
www.sandiegouniontribune.com - August 1 at 8:01 PM
nasdaq.com logoIonis Pharmaceuticals Inc. (IONS) Is Up Sharply On Phase 3 Study Results - Nasdaq (NASDAQ:IONS)
www.nasdaq.com - August 1 at 5:33 PM
investorplace.com logoWhy Ionis Pharmaceuticals Inc (IONS), Newell Brands Inc (NWL) and Trina Solar Limited (ADR) (TSL) Are 3 of Today's ... - Investorplace.com (NASDAQ:IONS)
investorplace.com - August 1 at 5:33 PM
thestreet.com logoBiogen and Ionis See Boost From Clinical Drug Trial (NASDAQ:IONS)
www.thestreet.com - August 1 at 5:33 PM
investors.com logoAre Biotechs Finally Making A Comeback? Here Are 5 Must-Watch Names (NASDAQ:IONS)
www.investors.com - August 1 at 5:33 PM
sg.finance.yahoo.com logoExxon Mobil and SolarCity skid; Caesars advances (NASDAQ:IONS)
sg.finance.yahoo.com - August 1 at 5:33 PM
News IconBiogen, Ionis: Nusinersen meets primary endpoint at interim analysis of trial (NASDAQ:IONS)
bolsafinanzas.com - August 1 at 10:25 AM
benzinga.com logoBiogen, Ionis Reveal Nusinersen Meets Primary Endpoint At Interim Analysis Of Final Stage ENDEAR Trial (NASDAQ:IONS)
www.benzinga.com - August 1 at 10:25 AM
News IconIonis Pharmaceuticals Inc (NASDAQ:IONS) Jumps 48% Right After The Call, Members made Huge Money (NASDAQ:IONS)
www.marketnewscall.com - August 1 at 10:25 AM
nasdaq.com logoIonis Pharmaceuticals Inc. (IONS) Is Up Sharply On Phase 3 Study Results (NASDAQ:IONS)
www.nasdaq.com - August 1 at 10:25 AM

Social

Ionis Pharmaceuticals (NASDAQ:IONS) Chart for Wednesday, August, 24, 2016


Last Updated on 8/24/2016 by MarketBeat.com Staff